Journal
OPEN OPHTHALMOLOGY JOURNAL
Volume 6, Issue -, Pages 54-58Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1874364101206010054
Keywords
Bevacizumab; age-related macular degeneration; nanospheres; microspheres; and controlled release
Categories
Ask authors/readers for more resources
Bevacizumab (Avastin (R)) has been used by ophthalmologists in many countries as an off-label drug for the treatment of wet age-related macular degeneration (AMD). Due to its short half-life necessitating frequent intravitreal injection, a method for sustained delivery is in need. We demonstrated that bevacizumab could be released in a sustained fashion over 90 days from nano- and microspheres fabricated from poly(DL-lactide-co-glycolide) and poly(ethylene glycol)-b-poly(D,L-lactic acid), respectively. The drug release rate could be adjusted by alteration of the drug/polymer ratio. The use of such nano- and microspheres as bevacizumab delivery vehicles may improve the treatment of wet AMD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available